Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma

Journal of Clinical Oncology

Volumn 17, Issue 8, 1999, Pages 2546-2552

  Dodd, Paul M ^a   McCaffrey, John A ^a   Herr, Harry ^a   Mazumdar, Madhu ^a   Bacik, Jennifer ^a   Higgins, Geralyn ^a   Boyle, Mary G ^a   Scher, Howard I ^a   Bajorin, Dean F ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; METHOTREXATE; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PATIENT SELECTION; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

EID: 0032795983     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.8.2546     Document Type: Article

References (11)

1. Sternberg CN, Yagoda A, Scher HI, et al: Methotrexate, vinblastine doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Cancer 64:2448-2458, 1989
2. Scher HI, Norton L: Chemotherapy for urothelial tract malignancies: Breaking the deadlock. Semin Surg Oncol 8:316-341, 1992
3. Miller RS, Freiha FS, Torti FM: Surgical resection of residual tumor mass following chemotherapy for advanced transitional cell carcinoma. Oncology Munchen Sympomed 3:370-381, 1994
4. Einhorn LH, Roth BJ, Ansari R, et al: Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma. J Clin Oncol 12:2271-2276, 1994
5. Dimopoulos MA, Finn L, Logothetis CJ: Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cisplatinum-based chemotherapy. J Urol 151:598-601, 1994
6. Donat SM, Herr HW, Bajorin DF, et al: Methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and cystectomy for unresectable bladder cancer. J Urol 156:368-371, 1996
7. Gabrilove JL, Jakubowski A, Scher H, et al: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414-1422, 1988
8. Dodd PM, McCaffrey JA, Mazumdar M, et al: Phase II trial of intermediate-dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. Cancer 85:1145-1150, 1999
9. Seidman AD, Scher HI, Gabrilove JL, et al: Dose-intensification of M-VAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 11:408-414, 1993
10. McCaffrey JA, Hilton S, Mazumdar M, et al: Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional cell carcinoma. J Clin Oncol 15:2449-2455, 1997
11. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958